Summary of findings 8. 100 mg olorinab 3 times/day compared to 25 mg olorinab 3 times/day for the management of abdominal pain in Crohn's disease and inflammatory bowel disease.
100 mg olorinab 3 times/day compared to 25 mg olorinab 3 times/day for the management of abdominal pain in Crohn's disease and inflammatory bowel disease | |||||
Patient or population: people with Crohn's disease Setting: unstated (multicentre, USA) Intervention: 100 mg olorinab 3 times/day Comparison: 25 mg olorinab 3 times/day | |||||
Outcomes | Anticipated absolute effects* (95% CI) | Relative effect (95% CI) | № of participants (studies) | Certainty of the evidence (GRADE) | |
Risk with 25 mg olorinab 3 times/day | Risk with 100 mg olorinab 3 times/day | ||||
Treatment success as defined by the authors | ‐ | ‐ | ‐ | ‐ | Not measured |
Pain frequency or change in pain frequency | ‐ | ‐ | ‐ | ‐ | Not measured |
Pain intensity (30% reduction in weekly AAPS) | Study population | RR 0.66 (0.38 to 1.15) | 14 (1 study) | ⊕⊝⊝⊝ very low a b | |
1000 per 1000 | 660 per 1000 (380 to 1000) | ||||
Withdrawal due to adverse events | 0 per 1000 | 0 per 1000 (0 to 0) | Not estimable | 14 (1 study) | ⊕⊝⊝⊝ very low a b |
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: confidence interval; RR: risk ratio | |||||
GRADE Working Group grades of evidence High certainty: We are very confident that the true effect lies close to that of the estimate of the effect. Moderate certainty: We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. Low certainty: Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect. Very low certainty: We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. |
aDowngraded one level due to risk of bias. bDowngraded two levels due to imprecision from very sparse data.